L

Lannett Company Inc
F:LN5

Watchlist Manager
Lannett Company Inc
F:LN5
Watchlist
Price: 2.254 EUR
Market Cap: 24.3m EUR

Relative Value

There is not enough data to reliably calculate the relative value of LN5.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LN5 Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0.1
Median 5Y
0.1
Industry
2.6
Forward
0.1
vs History
vs Industry
Median 3Y
-0.1
Median 5Y
-0.1
Industry
21.7
Forward
-5.3
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-3.6
Industry
16.6
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.6
Industry
22.5
vs History
vs Industry
Median 3Y
-0.1
Median 5Y
-0.1
Industry
2.3
vs History
vs Industry
Median 3Y
1.8
Median 5Y
1.8
Industry
2.9
Forward
1.3
vs History
vs Industry
Median 3Y
18.3
Median 5Y
18.3
Industry
5.5
vs History
vs Industry
Median 3Y
-16.9
Median 5Y
-16.9
Industry
13.1
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-8.7
Industry
16.6
vs History
vs Industry
Median 3Y
-85.4
Median 5Y
-85.2
Industry
15.8
vs History
vs Industry
Median 3Y
-34.5
Median 5Y
-34.5
Industry
19.1
vs History
vs Industry
Median 3Y
2.3
Median 5Y
2.3
Industry
1.9

Multiples Across Competitors

LN5 Competitors Multiples
Lannett Company Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Lannett Company Inc
F:LN5
24.3m EUR 0.1 -0.1 -17 -8.7
US
Eli Lilly and Co
NYSE:LLY
954.7B USD 16.1 51.9 34.8 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
505.3B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
252.4B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
209.5B GBP 4.8 29.9 108.3 158.6
CH
Novartis AG
SIX:NOVN
203.3B CHF 4.6 17.7 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
246.3B USD 3.8 12.9 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
206B USD 88.8 -70.5 326.5 818.8
US
Pfizer Inc
NYSE:PFE
146.7B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
L
Lannett Company Inc
F:LN5
Average P/E: 23.5
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -70.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
L
Lannett Company Inc
F:LN5
Average EV/EBITDA: 438.2
Negative Multiple: -17
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
326.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
L
Lannett Company Inc
F:LN5
Average EV/EBIT: 1 879.9
Negative Multiple: -8.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
818.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3